SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02495233

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Phase 1b/2 Study of ASP2215 in Combination With Erlotinib in Subjects With EGFR Activating Mutation-Positive (EGFRm+) Advanced NSCLC Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

The purpose of the Phase 1b part of the study was to evaluate the safety and tolerability of ASP2215 in combination with erlotinib and determine the recommended phase 2 dose (RP2D) of ASP2215. The purpose of the Phase 2 part of the study was to evaluate the objective response rate (ORR) of the RP2D of ASP2215 in combination with erlotinib.

NCT02495233 Non-Small-Cell Lung Cancer
MeSH: Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO: Neoplasm of the lung Non-small cell lung carcinoma

2 Interventions

Name: Gilteritinib

Description: oral

Type: Drug

Gilteritinib 120mg + Erlotinib 150mg Gilteritinib 80mg+ Erlotinib 150mg

Name: Erlotinib

Description: oral

Type: Drug

Gilteritinib 120mg + Erlotinib 150mg Gilteritinib 80mg+ Erlotinib 150mg


Primary Outcomes

Measure: Number of Participants With Dose Limiting Toxicities (DLTs)

Time: Cycle 1 and Cycle ≥2 (up to 141 days)

Description: Treatment-emergent adverse events (TEAE) was defined as an adverse event (AE) that started after administration of the study drugs and occurred within 30 days of the last dose of the study drugs. If a participant experienced an event both during the preinvestigational period and during the investigational period, the event was considered a TEAE only if it worsened in severity.

Measure: Number of Participants With Adverse Events

Time: From first dose of study drug up to 30 days after the last dose of study (maximum study drug exposure 114 days)

Secondary Outcomes

Measure: Area Under the Concentration-time Curve at 24 Hours (AUC24) for Gilteritinib

Time: 0, 0.5, 1, 2, 4, 6, 24 hours post-dose on Days 1 and 28 of cycle 1

Measure: Maximum Concentration (Cmax) for Gilteritinib

Time: 0, 0.5, 1, 2, 4, 6, 24 hours post-dose on Days 1 and 28 of cycle 1

Measure: Time After Dosing When Cmax Occurs (Tmax) for Gilteritinib

Time: 0, 0.5, 1, 2, 4, 6, 24 hours post-dose on Days 1 and 28 of cycle 1

Description: All participants in Gilteritinib 120 mg + Erlotinib 150 mg group discontinued before cycle 3.

Measure: Concentration Immediately Prior to Dosing at Multiple Dosing (Ctrough) of Gilteritinib

Time: Predose on Day 1, 3, 8, 15, 22, 28 of cycle 1, Day 1 of cycle 3 and Day 1 of cycle 4

Measure: AUC24 of Erlotinib

Time: 0, 0.5, 1, 2, 4, 6, 24 hours post-dose on Day 28 of cycle 1

Measure: Cmax of Erlotinib

Time: 0, 0.5, 1, 2, 4, 6, 24 hours post-dose on Day 28 of cycle 1

Measure: Tmax of Erlotinib

Time: 0, 0.5, 1, 2, 4, 6, 24 hours post-dose on Day 28 of cycle 1

Measure: Ctrough of Erlotinib

Time: Day 8, 15, 22, 28 of cycle 1

Description: ORR was defined as Objective Response Rate (ORR) was the proportion of patients whose best overall response was complete response (CR) or partial response (PR) per RECIST version 1.1. Only patients with measurable disease at baseline were to be included in the analysis of ORR.

Measure: Objective Response Rate (ORR) in Phase 1b

Time: End of treatment (approximately 4 months)

Purpose: Treatment

Allocation: Non-Randomized

Parallel Assignment


There are 2 SNPs

SNPs


1 L858R

- Participant had a documented exon 19 deletion or exon 21 L858R EGFR activating mutation. --- L858R ---


2 T790M

- Participant's baseline tumor specimen (obtained after participant developed resistance to EGFR TKI therapy) is T790M negative. --- T790M ---

- Participant received any agent with antitumor activity (other than an EGFR inhibitor, including a T790M inhibitor) including chemotherapy, radiotherapy, immunotherapy, within 14 days prior to the first dose of study drug (palliative radiotherapy is allowed). --- T790M ---



HPO Nodes


HPO:
Neoplasm of the lung
Genes 61
REST GPC3 WT1 HPGD BRAF PIK3CA TP53 TRIM28 RB1 TRIP13 SLCO2A1 AKT1 CASP8 KRAS TSC1 POU6F2 EWSR1 PRKN LMNA NAB2 TERT TSC2 SLC22A18 BRCA2 PPP2R1B STAT6 STK11 MUC5B ERBB2 TSC2 MBTPS2 BAP1 TSC2 DICER1 PDGFRB PERP EGFR TSC1 DIS3L2 NOTCH3 KEAP1 DICER1 DICER1 WT1 TSC1 C11ORF95 IRF1 CYP2A6 WRN RELA WT1 PTEN SFTPC SFTPA2 ERCC6 TRPV3 TP53 H19 TRIM28 FASLG MAP3K8
Non-small cell lung carcinoma
Genes 3
TP53 TP53 BAP1